Home > Category > Pharmaceutical > Target Product Profiles: Physician Insights on Key Attributes - Dyslipidemia, An HDL-raising drug that has a lower discontinuation rate than extended-release (ER) niacin for the treatment of dyslipidemia.
Market Research Report
Target Product Profiles: Physician Insights on Key Attributes - Dyslipidemia, An HDL-raising drug that has a lower discontinuation rate than extended-release (ER) niacin for the treatment of dyslipidemia.
|
|
PDF by E-Mail Approx. 1-2 business days
Hard Copy/CD-ROM Approx. 3-4 business days
If you need expedited delivery, please call us.
|
|
Table of Contents
- Introduction
- Using Target Product Profiles in Your Market Strategy
- Report Contents
- Target Product Profile Methodology
- Etiology and Pathophysiology
- Overview
- Lipid Pathways and Mechanisms
- Types of Lipoprotein and Lipoprotein Components
- Lipoprotein Generation and Transport
- Pathophysiology
- Dyslipidemia and Cardiovascular Disease Risk
- Cardiovascular Disease Markers in Dyslipidemia and Atherosclerosis
- Etiology
- Primary Dyslipidemia
- Secondary Dyslipidemia
- Target Product Profile Discussion-Dyslipidemia
- Target Product Profile Summary for Dyslipidemia-2011
- Assessing Drug Development Opportunities
- Physician Survey Results
- Effi cacy
- Safety and Tolerability
- Delivery
- Estimated Patient Share
- Pricing Potential
- Forecasted 2016 Pricing Environment
- Competitors to Watch
- Emerging Product Profiles
|
Related Report
|
|
Please inform me when related publications are released
|
| 
View Cart
